Anti-androgen hormonal therapy for cancer and other diseases
- PMID:31712062
- DOI: 10.1016/j.ejphar.2019.172783
Anti-androgen hormonal therapy for cancer and other diseases
Abstract
The development of targeted therapies has been a consistent goal for hormone-related diseases treatment. As a result of increased knowledge of the role of androgens in different diseases, anti-androgen treatment is becoming increasingly important in targeted therapy. Androgens play an important role in different disorders, therefore, androgen receptor signalling is a crucial factor in pathological conditions. The androgen receptor is a transcription factor activated by the testosterone metabolite 5α-dihydrotestosterone and regulates the expression of genes related to sexual differentiation, growth and survival of prostate cells, and to a certain extent, cancer progression. Herein, we review anti-androgen therapies in cancer and other selected diseases and provide examples where anti-androgen drugs can be used as both main and supportive treatments in the multimodal therapeutic scheme. Even in diseases with low serum levels of testosterone or DHT, anti-androgen therapy plays an important role in new treatments. Therefore, the use of anti-androgens is an appealing strategy in which to overcome resistance to primary treatment by assuring better therapy results. In this review, we take into account both older generation hormonal drugs and the new drug classes. Additionally, we review recent studies that suggest new anti-androgen agents have not entirely replaced some of the old standards.
Keywords: Androgens; Anti-androgen drugs; Breast cancer; Cancer therapy; Hormonal therapy; Prostate cancer.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
- Hormonal therapy of prostate cancer.Labrie F.Labrie F.Prog Brain Res. 2010;182:321-41. doi: 10.1016/S0079-6123(10)82014-X.Prog Brain Res. 2010.PMID:20541672
- [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].Murez T, Basset V, Audenet F, Lebret T, Branchereau J.Murez T, et al.Prog Urol. 2013 Oct;23 Suppl 1:S1-8. doi: 10.1016/S1166-7087(13)70040-X.Prog Urol. 2013.PMID:24314734Review.French.
- Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM.Klus GT, et al.Cancer Res. 1996 Nov 1;56(21):4956-64.Cancer Res. 1996.PMID:8895750
- Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.Hanamura T, Niwa T, Nishikawa S, Konno H, Gohno T, Tazawa C, Kobayashi Y, Kurosumi M, Takei H, Yamaguchi Y, Ito K, Hayashi S.Hanamura T, et al.Breast Cancer Res Treat. 2013 Jun;139(3):731-40. doi: 10.1007/s10549-013-2595-x. Epub 2013 Jun 19.Breast Cancer Res Treat. 2013.PMID:23780684
- Anti-androgens and other hormonal therapies for prostate cancer.Richie JP.Richie JP.Urology. 1999 Dec;54(6A Suppl):15-8. doi: 10.1016/s0090-4295(99)00449-5.Urology. 1999.PMID:10606279Review.
Cited by
- The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.Li L, Xu J.Li L, et al.Clin Transl Oncol. 2023 Feb;25(2):352-363. doi: 10.1007/s12094-022-02957-x. Epub 2022 Oct 6.Clin Transl Oncol. 2023.PMID:36203075Free PMC article.Review.
- Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies.Shiner A, Sperandio RC, Naimi M, Emmenegger U.Shiner A, et al.J Clin Med. 2024 Jan 27;13(3):734. doi: 10.3390/jcm13030734.J Clin Med. 2024.PMID:38337427Free PMC article.Review.
- The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy.Eltit F, Robinson N, Yu PLI, Pandey M, Lozada J, Guo Y, Sharma M, Ozturan D, Ganier L, Belanger E, Lack NA, Perrin DM, Cox ME, Goldenberg SL.Eltit F, et al.Adv Exp Med Biol. 2023;1408:291-308. doi: 10.1007/978-3-031-26163-3_16.Adv Exp Med Biol. 2023.PMID:37093434
- Endocrine Disruptors and Prostate Cancer.Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D.Corti M, et al.Int J Mol Sci. 2022 Jan 21;23(3):1216. doi: 10.3390/ijms23031216.Int J Mol Sci. 2022.PMID:35163140Free PMC article.Review.
- Metabolic Response to Androgen Deprivation Therapy of Prostate Cancer.Chen Y, Lin PH, Freedland SJ, Chi JT.Chen Y, et al.Cancers (Basel). 2024 May 24;16(11):1991. doi: 10.3390/cancers16111991.Cancers (Basel). 2024.PMID:38893112Free PMC article.Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials